Physician profile
Nina Khachiyants
NPI 1376706887
$1,578.72
in general payments reported to CMS, 2019-2025
16 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $63.40 · 2021: $71.14 · 2022: $97.46 · 2023: $148 · 2024: $398 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $287.97 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $242.26 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $201.44 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $201.03 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $192.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $100.99 | 2024-2025 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $84.55 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $75.84 | 2019-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.73 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $32.51 | 2021-2022 | |
| Indivior INC. | $25.34 | 2024 | Sublocade |
| Allergan, INC. | $24.96 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.14 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $16.80 | 2024 | Cobenfy |
| Lundbeck LLC | $16.76 | 2024 | Abilify Asimtufii |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.12 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Khachiyants listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.